Cargando…
The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631621/ https://www.ncbi.nlm.nih.gov/pubmed/35816636 http://dx.doi.org/10.1182/bloodadvances.2022007793 |
| _version_ | 1784823853469401088 |
|---|---|
| author | Ratain, Mark J. Tannock, Ian F. Lichter, Allen S. |
| author_facet | Ratain, Mark J. Tannock, Ian F. Lichter, Allen S. |
| author_sort | Ratain, Mark J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9631621 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96316212022-11-04 The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force Ratain, Mark J. Tannock, Ian F. Lichter, Allen S. Blood Adv Commentary American Society of Hematology 2022-08-30 /pmc/articles/PMC9631621/ /pubmed/35816636 http://dx.doi.org/10.1182/bloodadvances.2022007793 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. |
| spellingShingle | Commentary Ratain, Mark J. Tannock, Ian F. Lichter, Allen S. The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| title | The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| title_full | The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| title_fullStr | The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| title_full_unstemmed | The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| title_short | The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| title_sort | dosing of ibrutinib and related bruton’s tyrosine kinase inhibitors: eliminating the use of brute force |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631621/ https://www.ncbi.nlm.nih.gov/pubmed/35816636 http://dx.doi.org/10.1182/bloodadvances.2022007793 |
| work_keys_str_mv | AT ratainmarkj thedosingofibrutinibandrelatedbrutonstyrosinekinaseinhibitorseliminatingtheuseofbruteforce AT tannockianf thedosingofibrutinibandrelatedbrutonstyrosinekinaseinhibitorseliminatingtheuseofbruteforce AT lichterallens thedosingofibrutinibandrelatedbrutonstyrosinekinaseinhibitorseliminatingtheuseofbruteforce AT ratainmarkj dosingofibrutinibandrelatedbrutonstyrosinekinaseinhibitorseliminatingtheuseofbruteforce AT tannockianf dosingofibrutinibandrelatedbrutonstyrosinekinaseinhibitorseliminatingtheuseofbruteforce AT lichterallens dosingofibrutinibandrelatedbrutonstyrosinekinaseinhibitorseliminatingtheuseofbruteforce |